Evotec's Radical Restructuring Secures Investor Backing Despite Bleak Outlook

Investors focus on Evotec's radical restructuring and cash infusion, overshadowing a disappointing 2026 forecast. Shares rose over 8% as the firm plans site closures and job cuts to save €75M annually.

Investors in German biotech firm Evotec SE delivered a surprising vote of confidence this week, sending shares sharply higher despite the company issuing a deeply disappointing financial forecast for 2026. The market's focus appears firmly fixed on a radical cost-cutting plan and a significant cash infusion, overshadowing near-term operational weakness.

The company's full-year 2025 results, released this week, painted a picture of a business split in two. While the group's total revenue saw a slight decline to EUR 788.4 million, the underlying performance of its divisions diverged dramatically. The Biologics segment emerged as the clear star, posting a 39% surge in revenue to EUR 259.4 million and standing as the group's sole profitable operational unit. In stark contrast, the traditional drug discovery and development (D&PD) services business struggled, with revenue falling 13.5% and the unit sliding into an operating loss of EUR 12 million. Management attributed the D&PD weakness to a persistently challenging market environment.

On a group level, Evotec reported an adjusted EBITDA of EUR 41.1 million for 2025, comfortably meeting its own guidance. The net loss for the year was nearly halved to EUR 103.5 million. The real story, however, lies in the painful medicine prescribed for the future.

To address its operational imbalances, Evotec is implementing a sweeping restructuring initiative dubbed "Project Horizon." The plan is severe: the company will shutter locations, reducing its global footprint from 14 sites to 10 by the end of 2027. Approximately 800 jobs will be eliminated, with the majority of cuts occurring this year. Management expects these measures to yield annualized cost savings of roughly EUR 75 million once fully realized.

The financial guidance for the current transformation year, 2026, underscores the scale of the challenge. Evotec anticipates revenue between EUR 700 million and EUR 780 million, with adjusted EBITDA projected to land between zero and EUR 40 million. This outlook fell well short of analyst expectations, which had centered on an EBITDA exceeding EUR 80 million. The company warned that restructuring costs, estimated at around EUR 100 million for the second half of 2026 alone, will heavily burden the current year's results.

Crucially, the financing for this costly overhaul appears secure. Evotec confirmed the pending sale of its stake in Tubulis to Gilead Sciences, which is expected to deliver an upfront payment of approximately USD 100 million in the second quarter. Analysts at RBC Capital Markets noted this cash injection equates to about 11% of Evotec's current market value, providing a vital liquidity buffer. The firm maintained its EUR 10.00 price target on the stock, characterizing the overall results as in line with expectations.

The market's reaction was decisively positive. Evotec shares closed yesterday's Xetra session at EUR 4.86, marking a weekly gain of 8.20% and recording the highest trading volume in the SDAX index. This rally signals investor approval of the aggressive restructuring path, even as activist shareholder MAK Capital increases pressure for a separate U.S. listing of the profitable Biologics unit—a move it argues could unlock over a billion euros in value.

With the annual general meeting scheduled for June 11, where industry veteran Dieter Weinand is set to assume the role of supervisory board chairman, management must now navigate the gap between a weak annual forecast and ambitious shareholder demands. The first tangible positive effects from the cost-saving program are not expected to hit the balance sheet until the latter half of 2026. Until then, the company's strengthened capital base will be the foundational pillar of its ambitious turnaround.